Antidrug Antibodies: B Cell Immunity Against Therapy

Scandinavian Journal of Immunology

Volumn 82, Issue 3, 2015, Pages 184-190

  Fogdell Hahn, A ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETA1A INTERFERON; BLOOD CLOTTING FACTOR 8; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTERFERON BETA SERINE; NATALIZUMAB; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIBODY; ANTIRHEUMATIC AGENT; BETA INTERFERON; DRUG; MONOCLONAL ANTIBODY; RECOMBINANT FACTOR VIII SQ;

ANTIBODY AFFINITY; ANTIBODY TITER; CLINICAL PRACTICE; DRUG CLEARANCE; DRUG EFFICACY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOPHILIA A; HEREDITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; T LYMPHOCYTE; ARTHRITIS, RHEUMATOID; B LYMPHOCYTE; IMMUNOLOGY; TREATMENT FAILURE;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; INTERFERON-BETA; MULTIPLE SCLEROSIS; PHARMACEUTICAL PREPARATIONS; TREATMENT FAILURE;

EID: 84939233551     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12327     Document Type: Review

References (82)

1. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013;72:1947-55.
2. Rup B, Pallardy M, Sikkema D et al. Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: Recommendations of the innovative medicines initiative ABIRISK consortium. Clin Exp Immunol 2015; doi:10.1111/cei.12652. [Epub ahead of print].
3. Shankar G, Arkin S, Cocea L et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J 2014;16:658-73.
4. Astermark J. Overview of inhibitors. Semin Hematol 2006;43:S3-7.
5. Graw J, Brackmann HH, Oldenburg J, Schneppenheim R, Spannagl M, Schwaab R. Haemophilia A: from mutation analysis to new therapies. Nat Rev Genet 2005;6:488-501.
6. Gouw SC, van den Berg HM, Oldenburg J et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012;119:2922-34.
7. Astermark J, Oldenburg J, Pavlova A, Berntorp E, Lefvert AK. Polymorphisms in the IL10 but not in the IL1beta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006;107:3167-72.
8. Pavlova A, Delev D, Lacroix-Desmazes S et al. Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A. J Thromb Haemost 2009;7:2006-15.
9. Chaves D, Belisario A, Castro G, Santoro M, Rodrigues C. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A. Int J Immunogenet 2010;37:79-82.
10. Lozier JN, Rosenberg PS, Goedert JJ, Menashe I. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia 2011;17:641-9.
11. Lu Y, Ding Q, Dai J, Wang H, Wang X. Impact of polymorphisms in genes involved in autoimmune disease on inhibitor development in Chinese patients with haemophilia A. Thromb Haemost 2012;107:30-6.
12. Pinto P, Ghosh K, Shetty S. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients. Haemophilia 2012;18:794-7.
13. Pergantou H, Varela I, Moraloglou O et al. Impact of HLA alleles and cytokine polymorphisms on inhibitors development in children with severe haemophilia A. Haemophilia 2013;19:706-10.
14. Astermark J, Oldenburg J, Carlson J et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006;108:3739-45.
15. Astermark J. FVIII inhibitors: pathogenesis and avoidance. Blood 2015;125:2045-51.
16. Kurnik K, Bidlingmaier C, Engl W, Chehadeh H, Reipert B, Auerswald G. New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development. Haemophilia 2010;16:256-62.
17. Reipert BM, van Helden PM, Schwarz HP, Hausl C. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors. Br J Haematol 2007;136:12-25.
18. Allain JP, Frommel D. Antibodies to factor VIII. V. Patterns of immune response to factor VIII in hemophilia A. Blood 1976;47:973-82.
19. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977;2:933.
20. Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome. Vox Sang 1999;77 (Suppl. 1):49-54.
21. Oldenburg J, Austin SK, Kessler CM. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective. Haemophilia 2014;20 (Suppl. 6):17-26.
22. Hausl C, Ahmad RU, Sasgary M et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005;106:3415-22.
23. Miao CH. Immunomodulation for inhibitors in hemophilia A: the important role of Treg cells. Expert Rev Hematol 2010;3:469-83.
24. Leissinger C, Josephson CD, Granger S et al. Rituximab for treatment of inhibitors in haemophilia A. A Phase II study. Thromb Haemost 2014;112:445-58.
25. Deisenhammer F. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009;23:379-96.
26. Hartung HP, Freedman MS, Polman CH et al. Interferon beta-1b-neutralizing antibodies 5 years after clinically isolated syndrome. Neurology 2011;77:835-43.
27. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006;8:E501-7.
28. Sominanda A, Rot U, Suoniemi M, Deisenhammer F, Hillert J, Fogdell-Hahn A. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 2007;13:208-14.
29. Klechevsky E, Morita R, Liu M et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008;29:497-510.
30. Hegde NR, Kaveri SV, Bayry J. Recent advances in the administration of vaccines for infectious diseases: microneedles as painless delivery devices for mass vaccination. Drug Discov Today 2011;16:1061-8.
31. Ternant D, Aubourg A, Magdelaine-Beuzelin C et al. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008;30:523-9.
32. Perini P, Facchinetti A, Bulian P et al. Interferon-beta (IFN-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo. Eur Cytokine Netw 2001;12:56-61.
33. Sominanda A, Hillert J, Fogdell-Hahn A. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent. J Neurol Neurosurg Psychiatry 2008;79:57-62.
34. Hermanrud C, Ryner ML, Engdahl E, Fogdell-Hahn A. Anti-interferon beta antibody titers strongly correlate between two bioassays and in vivo biomarker expression, and indicates that a titer of 150 TRU/mL is a biologically functional cut-point. J Interferon Cytokine Res 2014;34:498-504.
35. Sorensen PS, Deisenhammer F, Duda P et al. Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-27.
36. Bertolotto A, Capobianco M, Amato MP et al. Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group. Neurol Sci 2014;35:307-16.
37. Li DK, Zhao GJ, Paty DW. University of British Columbia MSMRIARGTSSG. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results. Neurology 2001;56:1505-13.
38. Group PPoRaDbIb-aSiMSS. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498-504.
39. Group PS, the University of British Columbia MSMRIAG. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36.
40. Polman CH, Bertolotto A, Deisenhammer F et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9:740-50.
41. Jungedal R, Lundkvist M, Engdahl E et al. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice. Mult Scler 2012;18:1775-81.
42. Giovannoni G, Barbarash O, Casset-Semanaz F et al. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther 2007;29:1128-45.
43. McKoy JM, Stonecash RE, Cournoyer D et al. Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion 2008;48:1754-62.
44. Sominanda A, Lundkvist M, Fogdell-Hahn A et al. Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. Arch Neurol 2010;67:1095-101.
45. Leger OJ, Yednock TA, Tanner L et al. Humanization of a mouse antibody against human alpha-4 integrin: a potential therapeutic for the treatment of multiple sclerosis. Hum Antibodies 1997;8:3-16.
46. Carruthers RL, Berger J. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice. Mult Scler Relat Disord 2014;3:419-30.
47. Sorensen PS, Hyldgaard Jensen PE, Haghikia A et al. Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. Mult Scler 2011;17:1074-8.
48. Calabresi PA, Giovannoni G, Confavreux C et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007;69:1391-403.
49. Lundkvist M, Engdahl E, Holmen C et al. Characterization of anti-natalizumab antibodies in multiple sclerosis patients. Mult Scler 2013;19:757-64.
50. Vennegoor A, Rispens T, Strijbis EM et al. Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013;19:593-600.
51. De Groot AS, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008;112:3303-11.
52. Cousens LP, Tassone R, Mazer BD, Ramachandiran V, Scott DW, De Groot AS. Tregitope update: mechanism of action parallels IVIg. Autoimmun Rev 2013;12:436-43.
53. Link J, Lundkvist Ryner M, Fink K et al. Human leukocyte antigen genes and interferon beta preparations influence risk of developing neutralizing anti-drug antibodies in multiple sclerosis. PLoS ONE 2014;9:e90479.
54. Hoffmann S, Cepok S, Grummel V et al. HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis. Am J Hum Genet 2008;83:219-27.
55. Buck D, Cepok S, Hoffmann S et al. Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis. Arch Neurol 2011;68:480-7.
56. Nunez C, Cenit MC, Alvarez-Lafuente R et al. HLA alleles as biomarkers of high-titre neutralising antibodies to interferon-beta therapy in multiple sclerosis. J Med Genet 2014;51:395-400.
57. Hedstrom AK, Ryner M, Fink K et al. Smoking and risk of treatment-induced neutralizing antibodies to interferon beta-1a. Mult Scler 2014;20:445-50.
58. Hedstrom A, Alfredsson L, Lundkvist RM, Fogdell-Hahn A, Hillert J, Olsson T. Smokers run increased risk of developing anti-natalizumab antibodies. Mult Scler. 2013;20:1081-5.
59. Odoardi F, Sie C, Streyl K et al. T cells become licensed in the lung to enter the central nervous system. Nature 2012;488:675-9.
60. Bartelds GM, Krieckaert CL, Nurmohamed MT et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011;305:1460-8.
61. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9:164-72.
62. Wolbink GJ, Vis M, Lems W et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:711-5.
63. Garrison L, McDonnell ND. Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann Rheum Dis 1999;58 (Suppl. 1):I65-9.
64. Chen DY, Chen YM, Tsai WC et al. Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2015;74:e16.
65. Daien CI, Daien V, Parussini E, Dupuy AM, Combe B, Morel J. Etanercept concentration in patients with rheumatoid arthritis and its potential influence on treatment decisions: a pilot study. J Rheumatol 2012;39:1533-8.
66. Jamnitski A, Krieckaert CL, Nurmohamed MT et al. Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012;71:88-91.
67. Hart MH, de Vrieze H, Wouters D et al. Differential effect of drug interference in immunogenicity assays. J Immunol Methods 2011;372:196-203.
68. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals "hidden" immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010;362:82-8.
69. van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis 2013;72:1680-6.
70. Garces S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2014;73:1138-43.
71. van Schie KA, Hart MH, de Groot ER et al. The antibody response against human and chimeric anti-TNF therapeutic antibodies primarily targets the TNF binding region. Ann Rheum Dis 2015;74:311-4.
72. Ducourau E, Ternant D, Lequerre T et al. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis 2014;73:1428-9.
73. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006;54:3782-9.
74. Ternant D, Ducourau E, Perdriger A et al. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol 2014;78:118-28.
75. Maini RN, Breedveld FC, Kalden JR et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998;41:1552-63.
76. Ternant D, Ducourau E, Fuzibet P et al. Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis. Br J Clin Pharmacol 2015;79:286-97.
77. Mire-Sluis AR, Barrett YC, Devanarayan V et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 2004;289:1-16.
78. Shankar G, Devanarayan V, Amaravadi L et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008;48:1267-81.
79. Gupta S, Indelicato SR, Jethwa V et al. Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 2007;321:1-18.
80. Gupta S, Devanarayan V, Finco D et al. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal 2011;55:878-88.
81. Koren E, Smith HW, Shores E et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 2008;333:1-9.
82. Buttel IC, Chamberlain P, Chowers Y et al. Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals 2011;39:100-9.